Barry D. Quart - 13 Jul 2021 Form 4 Insider Report for HERON THERAPEUTICS, INC. /DE/ (HRTX)

Role
Chief Executive Officer, Director
Signature
/s/ Lisa Peraza Attorney-in-fact for Barry D. Quart
Issuer symbol
HRTX
Transactions as of
13 Jul 2021
Net transactions value
+$8,268
Form type
4
Filing time
15 Jul 2021, 16:50:34 UTC
Previous filing
30 Jun 2021
Next filing
15 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HRTX Common Stock Other $21,249 +1,529 +1.6% $13.90 96,721 30 Apr 2021 Direct F1
transaction HRTX Common Stock Options Exercise +3,645 +3.8% 100,366 13 Jul 2021 Direct F2
transaction HRTX Common Stock Tax liability $12,981 -963 -0.96% $13.48 99,403 13 Jul 2021 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HRTX Restricted Stock Units Options Exercise $0 -3,645 -7.1% $0.000000 47,396 13 Jul 2021 Common Stock 3,645 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2021.
F2 Restricted stock units convert into common stock on a one-for-one basis.
F3 Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.
F4 The restricted stock units vest in 16 equal quarterly installments beginning three months after the date of grant (10/13/2020).